Get the Stockscreener App
2.95
1.34%
-0.04
Veru Inc stock is traded at $2.95, with a volume of 571.21K.
It is down -1.34% in the last 24 hours and up +39.15% over the past month.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
See More
Previous Close:
$2.99
Open:
$3.02
24h Volume:
571.21K
Relative Volume:
0.33
Market Cap:
$47.35M
Revenue:
$3.86M
Net Income/Loss:
$-19.20M
P/E Ratio:
-4.0533
EPS:
-0.7278
Net Cash Flow:
$-24.88M
1W Performance:
-9.51%
1M Performance:
+39.15%
6M Performance:
+30.53%
1Y Performance:
-51.16%
1-Day Range:
$2.8201
$3.08
1-Week Range:
$2.8201
$3.34
52-Week Range:
$2.05
$7.33
Veru Inc Stock (VERU) Company Profile
Name
Veru Inc
Sector
Industry
Phone
(312) 595-9123
Address
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.95 | 47.35M | 3.86M | -19.20M | -24.88M | -0.7278 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Canaccord Genuity | Buy |
| May-14-24 | Initiated | B. Riley Securities | Buy |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Jun-07-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Feb-09-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jul-03-18 | Initiated | Maxim Group | Buy |
View All
Veru Inc Stock (VERU) Latest News
Earnings call transcript: Veru Inc Q2 2026 shows improved financials - MSN
Veru Inc (VERU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Veru Inc (VERU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
This small-cap biotech just soared over 160% — what is the Novo Nordisk connection? - MSN
Veru teams up with Novo Nordisk for obesity combination therapy trial (VERU) - MSN
Veru Inc. (VERU) Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Declines Amid Pre-Revenue StatusSaaS Earnings Trends - newsline.com
Why is Veru stock rising 10% today? By Investing.com - Investing.com Australia
Why is Veru stock rising 10% today? - Investing.com
VERU Q1 2026 Earnings: EPS Beat by 58.72% Amidst Market SkepticismPre-Earnings Setup - newsline.com
Wall Street sees huge upside as Novo Nordisk backs biotech company - thestreet.com
Veru And 2 Other Intriguing Penny Stocks To Watch - Sahm
Novo Nordisk's Mixed Bag: Zenagamtide Data Delights, CagriSema Stumbles, Veru Deal Emerges - AD HOC NEWS
Novo Nordisk Wegovy Trial With Veru Adds Underappreciated Obesity Angle - simplywall.st
Veru (NASDAQ: VERU) Stock Price Surges Over 160% After Clinical Supply Deal With Novo Nordisk (NYSE: NVO) - foreignpolicyjournal.com
Veru (VERU) Stock; Surges 88% as Novo Nordisk Partners on Wegovy-Supported Clinical Trial - MEXC
Veru Stock Surges 167% After Novo Nordisk Backs Its Obesity Drug - MEXC
Veru (VERU) Stock Rockets 167% on Novo Nordisk Obesity Drug Partnership - MEXC
Veru Shares Pop on Novo Wegovy Tie-Up, Uncertainty Lingers Over Key Clause - TechStock²
Veru (VERU) Stock Explodes 167% on Novo Nordisk Obesity Drug Partnership - MoneyCheck
Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial - Yahoo Finance
Veru shares jump after Novo Nordisk deal draws traders - TechStock²
Veru stock holds at Outperform as Oppenheimer cites Novo deal - Investing.com
Veru (VERU) Stock Price, Quote, Charts & News - Invezz
Veru (VERU) surges 161.8% after disclosing Novo Nordisk Wegovy supply deal for obesity study - Quiver Quantitative
VERU Maintained by Canaccord Genuity -- Price Target Steady at $25 - GuruFocus
Veru Enters Supply Agreement With Novo Nordisk for Obesity Study; Shares Surge - Moomoo
Veru pact with Novo ‘significant event,’ says Canaccord - TipRanks
Veru announces clinical supply agreement with Novo Nordisk - TipRanks
This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection? - Stocktwits
Why is Veru stock surging today? By Investing.com - Investing.com Canada
Veru Inc. Enters Clinical Supply Agreement with Novo Nordisk for Phase 2B Plateau Clinical Study - marketscreener.com
Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU) - Yahoo Finance
Veru, Novo Nordisk partner on enobosarm-Wegovy trial - TipRanks
Veru (NASDAQ: VERU) secures Novo Nordisk Wegovy supply for Phase 2b obesity trial - Stock Titan
Acute Respiratory Distress Syndrome Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Veru, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeu - Barchart
VERU Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Share UptickEarnings Surprise Report - newsline.com
VERU Q1 2026 Earnings: Narrower-than-Expected Loss Beats Estimates by 58.7%Earnings Call Highlights - newsline.com
Veru 2Q Loss $2.74M >VERU - Moomoo
Veru Inc Stock (VERU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):